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[57] ABSTRACT 
Compounds selected from the group consisting of a 
compound of the formula 
. ' (I) 
0 CH3: 0 
M.,) 11' '1', 111 8:1? XR 
iWN || | I! N i \u/ 
l 0 1 iii 0 ‘I | o 
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and compound of the formula 
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NH 
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((3112);: 
wherein 
x is 1 or 2, 
Y is carbobenzoxy or benzoyl, and 
XR is 
N — N\ 
\ 
—0 N02 or —s-L /N. 
N 
1 
Ph 
have use as elastase enzyme inhibitors. Particularly 
potent are the L-proline diastereomers. 
Elastase Enzyme inhibitory compositions comprise a 
carrier and an elastase enzyme inhibiting amount of the 
compounds of the invention. 
A method of selectively inhibiting the enzyme elastase 
in an animal or a human in need of such treatment com 
prises administering to the animal or human an enzyme 
elastase inhibiting amount of one of the compounds of 
the invention or a composition thereof. 
19 Claims, No_ Drawings 
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NOVEL PEPTIDYL CARBAMATE INHIBITORS 
OF THE ENZYME ELASTASE 
TECHNICAL FIELD 
This invention relates to novel peptidyl carbamate 
inhibitors of the enzyme elastase. This invention also 
relates to novel synthetic routes to synthesize the pepti 
dyl carbamates of the invention and to methods of in 
hibiting the enzyme elastase with the compounds of the 
invention. 
BACKGROUND ART 
Proteinases from polymorphonuclear leukocytes and 
macrophages, especially elastases (human leukocyte 
elastase and cathepsin G), appear to be responsible for 
the chronic tissue destruction associated with in?amma 
tion, arthritis and emphysema. During infection or in 
?ammation the normal lung is protected from proteo 
lytic digestion by the protease inhibitor al-antiryspin. 
The protective mechanism appears to be non-operative 
in individuals with an a1-antitrypsin elastase inhibitors 
capable of replacing al-antitrypsin therefore appear to 
be useful in the treatment of pulmonary emphysema and 
related diseases. 
Several types of elastase inhibitors have been re 
ported in the literature. These include peptide chloro 
methyl ketones as described in “Inhibition of Human 
Leukocyte El‘astase by Peptide Chloromethyl Ke 
tones”, P. M. Tuhy and J. C. Powers, FEBS Letters, 50, 
359-61 (1975); “Speci?city of Porcine Pancreatic Elas 
tase, Human Leukocyte Elastase and Cathepsin G. Inhi 
bition with Peptide Chloromethyl Ketones", J. C. Pow 
ers, B. F. Gupton, A. D. Harley, N. Nishino and R. J. 
2 
duced emphysema in animal models there is consider 
able question whether such reactive agents could be 
used for treating emphysema in humans. (“Prevention 
, of Elastase Induced Experimental Emphysema by Oral 
10 
Administration of a Synthetic Elastase Inhibitor,” A. 
Janoff and R. Dearing, Am. J. Respir. Dis., 121: 1025-3 
(1980)). This is not surprising since the alkylating moi 
.eties in these inhibitors might render them toxic when 
used on a continuous basis. To be suitable for human 
use, an enzyme inhibitor has to show a high degree of 
selectively and must have minimal toxic side effects. As 
a result, most drugs are molecules that reversibly bind 
15 to speci?c enzymes or receptor sites. Examples are the 
20 
25 
30 
Whitley, Biochem. Biophys. Acta. 485, 156-66 (1977); 35 
azapeptides “Proteinase ‘Inhibitors. l. Inhibitors of Elas 
' tase”, C. P. Dorn, M. Zimmerman, S. S. Yang, E. C. 
Yurewicz, B. M. Ashe, R. Frankshun and H. Jones, J. 
Med. Chem., 20: 1464-68 (1977); "Reaction of Serine 
Proteases with Ala-amino Acid and Aza-peptide De 
rivatives”, J. C. Powers and B. F. Gupton, Meth. En 
zymol., 46: 208-16 (1977); sulfonyl fluorides “Speci?c 
ity and Reactivity of Human Leukocyte Elastase, Por 
cine Pancreatic Elastase, Human Granulocyte Cathep 
sin G, and Bovine Pancreatic Elastase, Human Granu 
locyte Cathepsin G, and Bovine Pancreatic Elastase, 
Human Granulocyte Cathepsin G, and Bovine Pancre 
atic Chymotrypsin with Arylsulfonyl Fluorides; “Dis 
covery of a new series of potent and speci?c irreversible 
Elastase Inhibitors”, T. Yoshimura, L. N. Barker and J. 
C. Powers, J. Biol. Chem., 257, 5077-84 (1982); hetero 
cyclic acrylating agents “Inhibition of Elastase and 
Other Serine Proteases by Heterocyclic Acylating 
Agents”, M. Zimmerman, H. Morman, D. Mulvey, H. 
Jones, R. Frankshun and B. M. Ashe, J. Biol. Chem., 
255: 9848-51 (1980); “Selective Inhibition of Human 
Leukocyte Elastase and Bovine a1-Chymotrypsin by 
Novel Heterocycles", B. M. Ashe, R. L. Clark, H. 
Jones and M. Zimmerman, J. Biol. Chem., 256: 11603-6 
(1981); imidazole N-carboxamides, W. C. Groutas, R. 
C. Badger, T. D. Ocain, D. Felker, J. Frankson and M. 
Theodorakis, Biochem. Biophys. Res. Commun., 95: 
1890 (1980); and p-nitrophenyl-N alkyl carbamates, 
"p-Nitrophenyl Carbamates as Active-Site-Speci?c 
Reagents for Serine Proteases”, R. E. Sco?eld, R. P. 
Werner and F. Wold, Biochemistry, 16: 2492 (1977). 
Although some peptide chloromethyl ketones have 
been shown to be effective in preventing elastase in 
8 
45 
65 
carbamate esters physostigmine and neostigmine which 
have been clinically used as inhibitors of acetyl choline 
esterases, A. G. Gilman, L. S. Goodman and A. 
Gilman, “The pharmacological Basis of Therapeutics", 
p. 101, MacMillan Publishing Co. (1980). 
A series of peptide elastase inhibitors were disclosed 
in US Pat. No. 4,643,991 to Digenis et al. Another 
group of polymer-bound elastase inhibitors was dis 
closed in US. application Ser. No. 242,294 by Digenis 
et al ?led on Sept. 9, 1988. 
There still remains a need in the art for compounds 
which are superior speci?c, active-site directed inhibi 
tors of the enzyme elastase without the concomrnittant 
detrimental features of other prior art compounds. 
SUMMARY OF THE INVENTION 
This invention relates to a compound of the formula 
selected from the group consisting of 
a compound of the formula 
I 
I | | I 
: 3: call‘? 5'): 0: i 0 
Meol I IN I l | 
WNX'G' IN N\"’{;XR 
i0 it °i - a 0a 
l l l (cum: : l 
: : : \NH: : : 
i la) 1 / i : l 
i i : Y : l i 
P6‘ P5 'P4 ‘P3 IP2 {P1 ‘P1’ 
and 
a compound of the formula 
Y (II) 
\ 
NH 
/ | 
(CH1)... , , 
1 ill i ' i 
.....: ta #1. is r! Y= 
W I N 'XR 
in {T ll: YT" - \"1' 
| | 
P6: P5 {P4 {P3 ‘P2 :p, 1?,’ 
wherein 
xislor 2, 
Y is carbobenzoxy or benzoyl, and 
XR= 
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This invention also provides an enzyme elastase in 
hibitory composition comprising 
an enzyme elastase inhibitory amount of the com 
pound of the invention, and 
a carrier. 
Also part of the invention is a method of inhibiting 
the activity of the enzyme elastase comprising adding to 
an enzyme solution an enzyme elastase inhibitory 
amount of the compound of the invention. 
This invention also relates to a method of selectively 
inhibiting the activity of the enzyme elastase in the 
presence of an enzyme selected from the group consist 
ing' of trypsin and chymotrypsin comprising adding to 
an elastase enzyme solution an enzyme elastase inhibi 
tory amount of the compound of the invention. 
Still part of this invention is a method of selectively 
inhibiting the enzyme elastase in an animal or human in 
need of such treatment comprising administering to said 
animal or human an enzyme elastase inhibiting amount 
of the compound of the invention. 
Other objects, advantages and features of the present 
invention will become apparent to those skilled in the 
art from the following discussion. 
BEST MODE FOR CARRYING OUT THE 
INVENTION 
This invention arose from the desire of providing 
novel, more potent and selective peptidyl carbamate 
inhibitors of the enzyme elastase. Thus, the present 
genus of peptidyl carbamate inhibitors incorporates 
derivatized lysine and ornithine residues into the P3 or 
P4 positions of the dipeptides, i.e., the compounds of 
formulas I and II. The present compounds resemble the 
desmosine cross-linking units in mature elastin, which is 
the natural substrate of the human leukocyte elastase 
enzyme. 
Thus, this invention provides certain novel substi 
tuted peptidyl carbamate compounds, pharmaceutical 
compositions containing these compounds, and meth 
ods for using these pharmaceutical compositions in the 
selective inhibition of the enzyme elastase without af 
fecting similar serine dependent proteases, e.g., trypsin 
and chymotrypsin. 
It is known from the art that proteases from polymor 
phonuclear leukocytes and macrophages, especially 
elastases (human leukocyte HL elastase and cathepsin 
G) appear to be responsible for the chronic tissue de 
struction associated with in?ammation, arthritis and 
emphysema. During infection or in?ammation, the nor 
mal lung is protected from proteolytic digestion by the 
protease inhibitor, al-antitrypsin. This protective mech 
anism appears to be non-operative in individuals with an 
ai-antitrypsin de?ciency due to genetic or other causes. 
Synthetic elastase inhibitors capable of replacing a1 
antitrypsin are therefore useful in the treatment of pul 
monary emphysema and related diseases. 
According to the present invention, a class of com 
pounds containing the carbamate functionality and 
oligopeptides have been found to be superior activesite 
directed inhibitors of the enzyme elastase in animals and 
humans. This class of compounds, therefore, provides 
25 
30 
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4 
an opportunity to ‘incorporate chemical moieties of 
increased affinity towards the enzyme, and greater ca 
pability for the transfer of the acylating moiety to the 
active site of the enzyme. The nature of the acylating 
moiety may be varied to optimize the duration of the 
enzymatic inactivation. 
The mechanism of the invention appears to take ad 
vantage of the fact that these carbamate esters will react 
with proteases and esterases at the carbonyl carbon by 
losing the alkoxy portion and transferring the car 
bamylating moiety to the active site of the enzyme. 
Acylation will then lead to recovery of enzymatic ac 
tivity. 
The present invention provides a series of carbamate 
compounds which are active in accordance with the 
above proposals as elastase enzyme inhibitors. These 
novel compounds are carbamates substituted by oligo 
peptides which are selected from the group consisting 
of 
a compound of the formula 
I I I n t , i (I) 
I 0: CH3‘ | 0| O. l I l 
MIA/"J. A,» "i M \NQVXR 
i" :‘f g! I N g u: 
=° l“ i . : °= 
5 : : (CHM: l i 
| l ' \ l l ' 
l l I NH: | I 
I : i / ' l : 
l : i Y i l : 
P5‘ P5 ‘P4 :P3 ‘P2 IP1 ‘P1’ 
and 
a compound of the formula 
Y (II) 
\ 
Nl-l 
/ l 
I | (CH2)x l | I | 
l 
', l I H l l l 
' °' = ' °' 0' Y : 
MCOM ' N I]. I“ IN I XR 
l" '5‘ "‘ YT“ : \n’l 
:0 in 0:l CH3 : O: 
I | I 1 
P6} P5 lP4 if’; ‘P2 {P1 {P1, 
wherein 
it is l or 2; 
Y is carbobenzoxy or benzoyl; and 
XR = 
N—N\  
-0 N02 or +s-4 /N. 
N 
l 
Ph 
In a more preferred and detailed embodiment the 
compound of the invention is selected from the group 
consisting of 
1. p-Nitrophenyl N-[(Methoxysuccinyl)-L-alanyl-L-ala 
nyl-L~prolylmethyl]-N-isopropylcarbamate, 
2. Methyl succinimide succinate 
3. t-Butyl Methoxysuccinyl-L-alanine ester, 
4. Methoxysuccinyl-L-alanine, 
5. Na-Methoxysuccinyl-L-alanyl-Nz-benzoyl-L-lysine, 


5,008,245 
9 
x is 1 or 2; 
Y is carbobenzoxy or benzoyl; and 
XR is 
' N — N\ 
I 
Pb 
Also a more preferred group of compounds of the 
invention are those having the formula 
(11) 
z 
& - ______ _..9___.._  
wherein 
it is l or 2; 
X is carbobenzoxy or benzoyl; and 
XR is ‘ 
15 
25, 
30 
10 
Two synthetic routes are provided herein to produce 
the p-nitrophenyl peptidyl carbamates of the invention. 
One of the synthetic routes is designed to incorporate D 
or L proline into the P2 position of the molecule in a 
stereospeci?c manner. Derivatives incorporating D 
proline, however, possess reduced elastase enzyme in 
hibitory properties when compared to their diastereo 
mers which incorporate L-proline at the P2 position. 
The ‘peptidyl carbamate inhibitors of the invention 
selectively inhibit the enzyme elastase, e.g., human leu 
kocy'te elastase (HLE) and porcine pancreatic elastase 
(PPE), with inhibitor dissociation constants ranging 
from 3X l0-6M to 2X l0-9M. 
All the peptidyl carbamate inhibitors of the invention 
have been found to selectively inhibit the enzyme elas 
tase without inhibiting other enzymes such as trypsin or 
chymotrypsin, amont other enzymes. 
The peptidyl carbamate inhibitors of the invention 
are desmosine-like derivatives incorporating L-lysine or 
L-ornithine residues at the P3 or P4 regions of their 
structures. These features simulate the protruding 
chains of desrnosine cross-linking units in mature elas 
tin. 
The present compounds are synthesized in general by 
methods which are improvements over the method 
described in US. Pat. No. 4,643,991 to Digenis et al, the 
entire content of which is incorporated herein by refer 
ence. The synthetic approach of this invention involves 
the coupling of the P6-P3 moieties of the inhibitor mole 
cules with the P2-P1 moieties as depicted in Scheme 1 
herebelow. 
Scheme 1 
General synthesis of desmosine-like peptidyl carbamates. Coupling of Pé-P} moiety with the Pg-Pl' moiety 
N02 
CH(CHs)2 
(l) isobutyl chloroformnte 
— 15' C., THF 
| I 
MeO| 
‘ I 
I 
P6 : P5 P4 l P3 
I 
Ph 
i N C(O) 
Z ; CH(CH3)2 
| l I 
I I : P2 , Pi { P1 V 
This coupling reaction is conducted in a solvent, 
preferably a polar solvent at low temperature. The 
conditions for this process are standard in the art and 
55 will be known to an artisan. ' 
The synthesis of methoxysuccinyl-alanine aminoacid 
dipeptides of the invention is depicted in Scheme 2 
herebelow 
Scheme 2 
Synthesis of the MeOSUC-Ala-Amino acid dipeptides. 
O§ EtsN, 
H N L-alanine 
3 _ t-but l ester 
EtOAc 9 Meosuc 0" THF 9 
o o 0* 
ll ll 
cmoccmcmc-cx + HON 
o’ 2 I 0/ 
5,008,245 
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-continued 
Scheme 2 
Synthesis of the MeOSUC'Ala-Amino acid dipeptides. 
_ _ Hcl/HcooH __ DDC NHS 
MeOSUC Ala x-Wmosuc Maw 
3 4 
°§ 
I 
_ __ . L s-Bz 31 _ _ MeOSUC All 0ND EUN’THF MeOSUC All Lys 
5 
/ 0/ Cbz-lysine (33) 
phenacyl ester, 
Et3N Cbz-ornithine (36) BUN THF 
THF phenacyl ester 
9” i? 
MeOSUC-Ala-Orn-OCl-bC- Ph 
8 
Zn 
HOAc 
Cbz 
Zn ' 
HOAc 
Cbz 
MeOSUC—Ala—Om 
Cbz 
MeOSUC-Alr-Lys 
9 7 
_ The synthesis of methoxysuccinyl-alanine aminoacid 
dipeptides in which the aminoacid residue can be omi 
thine (residue 9) or lysine (residue 7) with carbobenzoxy 
(Cbz) or benzoyl (Bz) groups at their terminal amine 
function (N;) is shown in Scheme 2. These reactions are 35 
conducted under standard conditions which are known 
to an artisan. 
The synthesis of methoxysuccinyl-aminoacid-alanine 
dipeptides is depicted in Scheme 3 herebelow. 
Scheme 3 
_Synthesis of the MeOSUC-Amino acid-Ala dipeptides 
‘\ 
MeOSUC-ON 
Z 
/ 
/ 0/ \ 
Cliz Cbz 
MeOSUC-Om MeOSUC-Lys 
lo \L 13 \L 
0 O \ \ 
Cbz \ Cbz \ 
MeOSUC-Om-ON MeOSUC-Lys—ON 
/ 
Cliz Cbz 
MeOSUC-0m-Ala-X MeOSUC-Lys—Alr-X 
ll 1/ l4 1/ 
45 
50 
55 
65 
O 
I ll 
MeOSUC-Ala-Lys-OCl-hC-Ph 
-continued 
Scheme 3 
_Synthesis of the MeOSUC-Amino acid-Ala dipeptides 
Cbz Cbz 
MeOSUC—Orn—Ala MeOSUC- Lys- Ala 
l5 12 
1'32 
MeOSUC- Lys 
0 
16 \l/ 
B: 
MeOSUC- Lys—ON 
O M 
MeOSUC-Lys-Ala-X 
17 \l/ 
B: 
l 
MeOSUC- Lys—Ala 
l8 
// 
X = t-butyl ester 
As previously indicated the aminoacid residue could 
be omithine or lysine with carbobenzoxy or benzoyl at 
their terminal amino functions (Ni). Examples of these 
compounds are represented by the structures of Com 
pounds 12, 15 and 18 which are products obtained in 
accordance with the procedure described in Scheme 3. 
The coupling of other inhibitor compounds similar to 
compounds 7 and 9 shown in Scheme 2 with intermedi 
ate compound 22 appearing in Scheme 4 results in the 
synthesis of the compounds 48-51 shown in Table 2 
below. 
5,008,245 
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TABLE 2 
Inhibition of HLE. by Desmosine-like Peptidyl Carbamates- Variations in P3 
1 P1 . 
1 : o 0 CH3 1 H 01 
CH O n l!‘ H l " \Nr 0 
3 \/\/\N | WAN V ll 1 ll i ll 
0 O‘ R O 
| NO; 
center of asymmetry 
(L or D proline) 
K!‘ values (EM! 
Cpd. P3“ ' lsomerb Dixon‘ Replotd 
48 bk-Cbz-Lys (a) L 1.10 . 0.22 
(b) D 20.40 11.33 
49 N¢—Bz—Lys (a) L 1.60 0.31 
(b) D 34.00 38.50 
N5—Cbz—Orn (a) L 0.75 1.05 
(b) D 22.20 19.25 
51 N5—Bz-‘Orn (a) L 5.33 2.14 
(b) D 104.00 100.00 
"Cbz = carbobenzoxy; B1 = benzoyl; Lys = L-lysine; Om = L-ornithine. 
"I. k D refer to the con?guration at the prolyl u-carbon. 
‘Lines contained linear regression analysis correlations of >0.950. 
4K; values determined from Lineweaver-Burk slope replots. Slopes were obtained from lines with linear regression analysis 
correlations of >0.990. 
Table 2 provides Ki values for 2 diastereomers of 
each compound (a and b). In all cases the diastereomers Scheme 4 
incorporate L proline, where L or D refers to the con- 30 ‘Synthesis of P3-P1‘ moiety as the stable hydrochloride salt (22). 
(l) isobutyl chloroformate, 
N-methylmorpholine, 
diethyl ether, —20° C. 
(2) diazomethane, 5' C. 
tory activity against the enzyme elastase than their cor- 3s 
responding diastereomers derived from D-proline. 
The coupling of the intermediate compounds such as 
compounds '12, 15 and 18 shown in Scheme 3 with 35 
?guration at the propyla-carbon, exhibit greater inhibi- tmovljcoz? 
compound 22 shown in Scheme 4 herebelow results in O 
the synthesis of compounds 44-47 shown in Table 1 II + 
herebelow. Pam-N C_CH=N=NT. 
(3) RC1 (anhydrous), 5' C. TABLE 1 E \II 
Inhibition of HLE by Desmosine-like Peptidyl Carbamates; Variations in P‘ V 
P4 
1 1 
01 R |H Q 0 
CH 0 1|: 1| 1| \Nr 0 
3 ' w/\N Y 1 
0 i 11 0: C11, 0 
' N02 
optically active 
(center of asymmetry) 
. Ki value (a!) 
Cpd. P4" lsomer Dixon‘ Replotd 
44 Ng-Cbz-Lys (a) L 0.56 0.47 
' (b) D 7.30 7.63 
45 Nc-Bz-Lys (a) L 0.73 0.311 
(b) D 3.70 3.13 
46 Ng-Cbz-Orn (a) L 0.43 0.36 
(b) D 8.80 7.95 
47 Ng-Bz-Orn (a) L 0.65 0.19 
(b)D 10.00 17.70 
‘Co: = carbobenzoxy; B1 = benzoyl; Lys = L-lyaine; Orn = L-ornithine. 
"L t D refer to the con?guration at the prolyl aecarbon. 
"Lines ‘ ‘ linear , ‘ analysis w. ‘ ' of >0.950. 
‘K; values determined from Lineweaver-Burk slope replota. Slopes were obtained from lines with linar regression analysis 
correlations of >0.990. 
Scheme 4 is shown herebelow and provides the syn 
thesis of P3-P1 moieties as their stable hydrochloride 
salts (compound 22). 
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-continued -continued 
Scheme 4 Scheme 4 
Synthesis of P3—P1' moiety as the stable hydrochloride salt (22). gnthesis of P3~P1' moiety as the stable hydrochloride salt (22). 
l’ 5 t’ t 
9113;?!“ C_CH2C‘ HCLHN c-cnm-c-o N02 
isopropylamine, 22 i 
THF, 5' c. CH(CHs)z 
fl) /CH3 10 These reactions are also conducted under conditions 
t_-Boe-N C——CHZNH—CH which are standard in the art and would be known to an 
20 \CH artisan. 
3 As already indicated above here also the diastereo 
p'Ni‘mphmyl' rners incorporating L proline designated as a) are shown 
chloroformate. 
THF 5. C 15 to have a greater inhibitory capacity against the enzyme 
’ ' elastase, e.g. HLE, than those compounds derived from 
D-proline as shown in Table 1 above. 
0 0 V In all cases compound 22 is synthesized from com 
" ll @Noz pound 38 by a synthetic route which is shown in yam-N c_c?zllq_c_-O 20 Scheme 4 hereabove. 
CH(CHs)2 The stereo speci?c synthesis of compounds 44-51 
HCl (anhydrous), follows a synthetic procedure which is depicted in 
fonnic acid, Scheme 5 herebelow. 
ethyl acetate, 22' C. 
Scheme 5 
Stereospeci?c synthesis of desmosine-like peptidyl earbamates. 
O§ D- or L-proline 
Cliz Ctiz phenacyl ester, 
_ _ NHS ncc _ __ _ E'sN 
MeOSUC Ala Lys THF' 5. C MeOSUC Ala Lys ON THE 5. C 
7 / 
0/ 
isobutyl 
Cbz Cbz chloroformate, 
I Zn I N-meth lmo holine MeOSUC—Ala—Lys-Pro—Y “CA6 25. C MeOSUC-Ala-Lys-Pro —% 
23 or 24 25 or 26 
Cbz O 
0 
I ll - - 
_ _ _ 150 ro lamine 
MeOSUC Ala Lys-13C CHZCl clhy] “cute, 5. C‘ 
27 or 28 
p-nitrophenyl 
Ch: 0 CH3 chloroformate, 
Ii / EI3N 
Ci’ ii i’ 
MeOSUC—Ala—Lys—-N c-cnnr-c-oG N02 
Z ; CH(CH3)2 - 
48: or 48b 
29 or 30 
Y = phenaeyl ester 
As in the previous cases the conditions for conduct 
65 ing the various steps in this method are standard in the 
art and would be known to an artisan. 
The peptidyl carbamate inhibitor of Formula 46 may 
be synthesized from all L aminoacids (L-L isomer). 
5,008,245 
17 18 
When tested against human leukocyte elastase enzyme functionality at P1 of Formulas I and II by N-phenylthi 
it is evidenced that its inhibitory activity may be en- otetrazole. This results in compounds PCS and PC6 
hanced by utilizing a 50:50 mixture of the two diastereo- which were shown to have Ki values of 2.0 X 10- 3M to 
mers which result from the incorporation of D or L 3X l0-9M respectively. 
li’h PCS 
0 CH3 H o 0 
n I II II Y N 
“CONN N N NVS \ i1: 
II i II II N/ 
o H 0 O 
NH 
\ 
CBz 
CB2 PC6 
NH 
l|>h 
N 0 H 0 \ 
Meo n IIq II II N S__< ‘If 
\/\/\N \'/\N v \ N 
II I II II N/ 
o 0 cn; o 
proline into the structure of compound 46. The coupling of the intermediate 7 with the com 
Table 3 below shows the effect of the stereo chemis- pound 54 results in the elastase enzyme inhibitory com 
try at P; on the elastase enzyme inhibitory activity of 35 pound PCS. The coupling of compound 12 with com 
compound 46 of this invention. pound 54 results in the elastase enzyme inhibitory com 
TABLE 3 
Effect of Stereochemistry at P; on the HLE Inhibitory Activity 
o H o 0 
cno " it ‘I \Nr 0 
3W’? n 5”“ \u’ 
o u 0 ca; 0 
N02 
ll 
Compound K,- value‘ km“ 
(46) (1M) (5‘ l) (M- ‘s- 1) kobs/[nc 
L-L-L 0.65 0.376 x237 
L-IrD-proline 7.95 0.021 461 
L-L-DLd 0.42 0.437 _ 9537 
‘K; value was determined by steady state 
‘First and second order rate constants were determined by predatudy state inhibition kinetia. 
‘n50 mixture of two inhibitors, each contributing 3.8 X 10-7 M. 
Extremely highly potent inhibitors of the enzyme pound PC6. The synthesis of these compounds are de 
elastase are obtained by replacing the p-nitrophenyl picted in Scheme 6 below. 
7 Scheme6 
Synthesis of PCS and PC6 
Preparation of thiocar‘ portion. 
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The conditions for conducting the various steps en 
compassed by these methods are known in the art and to 
an artisan in the ?eld. 
As pointed out above, the compounds of the inven 
tion may be’ employed as speci?c active site directed 
inhibitors of the enzyme, elastase. For this purpose, the 
compounds are preferably combined with a pharmaceu 
tically acceptablecarrier for administration by injection 
or in the oral form. Conventional adjuvant and carriers 
may be employed in combination with about 0.001 to 
2.0 weight percent of the active compound. The com 
pounds may be administered to animals or humans at 
about 10 mg/kg, preferably an average amount of about 
6 mg/kg. 
The following examples illustrate preferred embodi 
ments of the invention but the invention is not consid 
ered to be limited thereto. In the examples and through 
out this speci?cation, parts are by weight unless other 
wise indica'ted. _ ' 
In synthesis of the compounds of the invention, melt 
ing points were determined on a Thomas-Hoover Uni 
Melt apparatus and are uncorrected. 1H NMR spectra 
were obtained using a Varian EM-360 (60 MI-I2O or 
EMg-390) (90 MHz) spectrometer. Infrared (IR) spectra 
were recorded on a Perkin-Elmer 567 spectrophotome 
ter. Microanalyses were performed by Atlantic .Mi 
crolab, Inc., Atlanta, Ga. or by Micro Analysis, Inc., 
Wilmington, Del. 
Reactions were routinely followed by thin layer 
chromatography (TLC) using Whatman MK6F silica 
gel plates. Spots were detected by UV (254 nm), iodine 
or HBr-Ninhydrin spraying. Column chromatography 
was carried out using Silica Gel 60 from E. Merck, 
Darmstadt, Germany. All compounds were identi?ed 
by spectral data and elemental analysis. 
Having now generally described this invention, the 
same will be better understood by reference to certain 
speci?c examples, which are included herein for pur~ 
poses of illustration only and are not intended to be 
limiting of the invention or any embodiment thereof, 
unless so speci?ed. 
EXPERIMENTAL 
EX. 1 
Methyl succinimide succinate (2) 
O 2 
o H Ha, H], 
n " "b 
CHS‘O/Yk?/ON Hb _ 
H“ H‘ 0 ll Ho 
0 . 
This compound was synthesized by a modi?ed proce 
dure of Digenis et a1.39 . 
A solution of 3-carbomethoxypropionyl chloride (5 
g, 33.2 mmoles) and N-hydroxysuccinimide (3.8 g, 33.2 
mmoles) in ethyl acetate (60 ml) was cooled to 5' C. 
While stirring, triethylamine (4.3 g, 33.2 mmoles) was 
slowly added to the cooled solution over a 15 min inter 
val. The mixture was allowed to equilibrate to room 
temperature (22' C.) and react for an additional 3 h. The 
formed triethylamine salt was ?ltered, washed with 
ethyl acetate and the ?ltrate evaporated under vacuum. 
The powderwas recrystallized from ethyl acetate/hex 
ane to give 5.5 g (24.2 mmoles) (72% yield) of white 
15 
30 
35 
45 
55 
65 
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(4Hb,s); 3.66(3Hc,s)ppm. IR (Nujol) 1840, 1800, 1775, 
1725 cm—1‘~ 
EX. 2 
t-Butyl Methoxysuccinylalanine ester (3) 
O H ' H ' O 
u c ‘ 31 a, u 
CHJQO 0C(CHs)sb 
To an ice cooled suspension of the activated ester 
_ 2(3.6 g, 16 mmoles) and L-alanine t-butyl ester (2.3 g, 16 
mmoles) in THF (50 mL), triethylamine (2.0 g, 16 
mmoles) in THF (1 mL) was added dropwise. The 
progress of the reaction was monitored by TLC (10% 
methanol in chloroform) and stirred at 5‘ C. for 3.5 h. 
The precipitate was ?ltered under vacuum and washed 
with ethyl acetate. The residual oil, containing the 
product, was chromatographed using 40 g of silica gel 
column (2X 50 cm). Impurities were eliminated by ?rst 
passing 50 mL of methylene chloride and subsequently 
compound 3 was eluted with 2%. methanol in methy 
lene chloride. Upon evaporation of the eluent solvent 
under reduced pressure the product was obtained. The 
latter was then crystallized from ethyl acetate/pe 
troleum ether to give 2.9 g (11.3 mmoles) (71% yield) of 
a crystalline powder vmp 9l°-92‘ C. lH-NMR (CDCl3) 
6 l.36(3H,',,d, J=8Hz); l.46(9Hb,s); 2.44(2H¢,app.t, 
J =8I-Iz); 2.64(2Hc',app.t, J =8I-Iz); 3.66(3Hd,s); 
4.20—4.60(1H,,m); 6.85(lHf,m, rotamer of amide 
-—NH)ppm. IR (CDC13) 3400, 1815, 1785, 1740 cm-‘. 
EX. 3 
Methoxysuccinylalanine (4) 
O H ' H ' H: 
H a b 1!‘ 
CHM-0 H 
0 
0 
H4 OH] 
H], Hb CH3, 
The t-butyl ester 3 was hydrolyzed by either of the 
following methods in good yield. 
Procedure A: 
Formic acid (98%)(l.5 mL) was added to an ice 
cooled solution of 3 (1.0 g, 3.9 mmoles) dissolved in 
ethyl acetate (10 mL). Hydrogen chloride gas was 
slowly bubbled through the cooled solution in two 
short (30 s) intervals 10 min apart. The solution was 
allowed to warm to room temperature and stirred for 2 
h. The volatile liquids were evaporated in vacuo. The 
residue, containing the product, was chromatographed 
on 15 g of silica gel column (1 X25 cm). The product 4 
‘was eluted with 4% methanol in methylene chloride. 
Upon evaporation of the eluent solvent under reduced 
pressure 0.77 g (3.8 mmoles) (98% yield) of a transpar 
ent oil was obtained. 
Procedure B: 
A solution of 3 (1.0 g, 3.9 mmoles) in glacial acetic 
acid (5 mL) at room temperature was slowly diluted 
with 30% HBr in acetic acid (5 mL) and stirred for 30 
min. The reaction was stopped by the addition of ice 
water (15 mL) and the ?ne suspension was extracted 
with methylene chloride (5 X 25 mL). The organic layer 
was washed with brine, dried (5 g of MgSO4), and the 
solvent was azeotropically removed under vacuum 
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using n-heptane. The product was chromatographically 
puri?ed as described in Procedure A, to give 0.77 g (3.8 
mrnoles) (98% yield) of a transparent oil. XH-NMR 
(CDC13) 8 1.36(3Ha,d, J =8I-lz); 2.56(4H1,,b',app.t, 
1:81-12); 3.66(3Hc,s);4.20-4.60(lHd,m); 6.56(1He,m, 
rotamer of amide —NH); 9.50(lHf,s)ppm IR (CI-ICl3) 
5 
24 
—NH); 9.56(lHm,s)ppm. IR (CHC13) 3330, 1730, 1645, 
1600, 1540 cm—1. 
EX. 5 
Na-Methoxysuccinylalanyl-Ne-carbobenzoxylysine 
phenacyl ester (6) 
I Hg 
0 H8 
=0 
Ell-N H4 
Hb 
Hb Hd 
Hb Hb 
Hb 
r i“ if if H | N Hf b O a 
CHM-‘O m’ 
He He 0 C1139 Hf O H}, H}, a n 
3280, 1735, 1690, 1630, 1540 cm-1. 
EX. 4 
Na-Methoxysuccinylalanyl-Ne-benzoyllysine (5) 
Ht’ H5 “I: 0 
ll Ha 
O 
11 IL Hf 
CHKd-O \*/\N ll | 
O He H: CH3: H; 
on; 
“f ll 
0 
This compound was prepared from N¢»benioyl-L 
lysine (not the phenacyl ester) according to an analo 
gous procedure to that described for 6, with the follow 
ing changes: the solvent was changed to DMF, the 
reaction time was extended to 24 h and the eluting sol 
vent was changed to 8% methanol in chloroform. Upon 
evaporation of the eluent solvent under reduced pres 
sure 0.37 _g (0.85‘ mrnoles) (47% yield) of a transparent 
oil was obtained. 1H-NMR (CDC13) 8 l.36(3Ha,d, 
J =8Hz); l.50—1.86(6H1,,m); 2.56(4Hc,¢',app. t, J=8Hz); 
3.23(2H4,m); 3.66(3He,s); 4.00-4.70(2Hf,m); 5.80(lHg,m, 
rotamer of amide —NH); 7.23(1H;,,m, rotamer of amide 
—NH); 7.34(2H,-,r,app. dd, J,-k=8Hz, J,-,~=2Hz); 
7.43(1Hj,app. dd, Jji=8HZ, Jjk=2HZ); 7.86(2Hk,k',app. 
ddJki=3Hl,Jkj=2Hz); 8.10(ll-I1,m, rotamer of amide 
30 
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Methoxysuccinylalanine (4) (0.37 g, 1.8 mrnoles) and 
N-hydroxysuccinimide (0.2 g, 1.8 mrnoles) were mixed 
in THF (3 mL) and cooled to 5' C. A concentrated 
solution of N,N'-dicyclohexylcarbodiimide (0.4 g, 1.8 
mrnoles) in THF was added dropwise to the cooled 
solution. The suspension was stirred for 14 h at 5' C., 
and the precipitated urea formed was ?ltered under 
vacuum. The ?ltrate was cooled to 5‘ C. and used in the 
next reaction without further puri?cation. 
To a mixture of Npcarbobenzoxylysine phenacyl 
ester hydrochloride (35) (0.7 g, 1.7 mrnoles) and the 
above N-hydroxysuccinimide ester in cooled THF (7 
mL), triethylamine (0.17 g, 1.7 mrnoles) in THF (0.5 
mL) was added dropwise. A solution was observed for 
a short period of time before a precipitate was formed. 
The progress of the reaction was monitored by TLC 
(10% methanol in chloroform). Upon completion of the 
reaction (4 h), the formed triethylamine salt was ?l 
tered, washed with ethyl acetate and the ?ltrate evapo 
rated under vacuum. The residue, containing the prod 
uct, was chromatographed on 15 g of silica gel column 
(1 X25 cm). Impurities were eliminated by ?rst passing 
50 mL of methylene chloride and subsequently the 
compound was eluted with 2% methanol in methylene 
chloride. Upon evaporation of the eluent solvent under 
reduced pressure a hygroscopic product was obtained. 
The latter was then recrystallized from ethyl acetate/ 
diethylether to give 0.8 g (1.3 mmoles) (84% yield) of a 
crystalline powder, mp 1l4°—1 16' C. lH-NMR(CDC13,) 
8 l.36(3Ha,d, J =8Hz); l.50-2.20(6H1,,m); 2.44(2Hc,app. 
t, J=8Hz); 2.64(2H¢',app.t, J=8Hz); 3.23(2Hd, m); 
3.66(3He,s); 4.30-4.90(2Hf,m); 5.10(2Hg,s); 5.46(2H;,,s); 
5.80(1H,~,m, rotamer of amide —NH); 6.56(1Hj,m, 
rotamer of amide —NH); 7. 10(lHk,m, rotamer of amide 
—NH); 7.40(5H1,s); 7.63(3H,,,,,,,',,,,app. dd, J,,,0=8Hz, 
J mm’ = 21-12); 8.06(2H0,0',app. dd, J am = 81-12, 
J0,,=2Hz)pprn. IR (CHC13) 3330, 1755, 1730, 1645, 
1600, 1540 cm“. 
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EX. 6 
. Na-Methoxysuccinylalanyl-Ne-carbobenzoxylysine (.7) 
7 5 
l 
H: 
10 
o H, 
=0 
0 
ll 
CH3¢_O 
He 
H,—N n, 35 
H1, “d 
H1, HI’ 
“I: 
“b 
i: *r' a.’ Hf H5 
N 0H1. CH3 —0 N 
' ll l "I II 
R; H, 0 CH3, H’, O 45 
Small portions of zinc metal (total 2 g) were added 
over a l h period to a solution of phenacyl ester 6 (0.6 
g, 1.1 mmoles) in glacial acetic acid (10 mL). The reac 
tion was completed within one additional hour of stir 
ring at room temperature. The suspension was diluted 
with 20% methanol in chloroform (50 mL), ?ltered 
under vacuum and the precipitate washed with 50 mL 
of 20% methanol in chloroform. The ?ltrate, containing 
the product, was evaporated under reduced pressure. 
The residue was partially dissolved in 5% methanol in 
chloroform and ?ltered to remove the zinc oxide. The 
second ?ltrate was evaporated under reduced vacuum 
to an impure oil. The latter was dissolved in methylene 
chloride and chromatographed on 10 g of silica gel 
column (1X 25 cm). Impurities were eliminated by ?rst 
passing 100 mL of 2% methanol in methylene chloride 
and subsequently compound 7 was eluted with 5% 
methanol in methylene chloride. Upon evaporation of 
the el’uent solvent under reduced pressure an oil with a 
tendency to foam under vacuum was obtained. The 
product was crystallized from ethyl acetate/hexane to 
give 0.37 g (0.74 mm0le)(74% yield) of a crystalline 
50 
65 
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white powder, mp ll6°-ll8° C. lH-NMR (CDCl3) 5 
l.36(3Ha,d, J =8l-lz); 1.40-2.2O(6H1,,m); 2.56(4Hc,c',app. 
t, J=3HZ); 3.23(2Hd,m); 3.66(3He,s); 4.30-4.90(2Hf,m); 
5.10(2Hg,s); 5.60(lH/,,m, rotamer of amide —NH); 
6.80—7.20(2H,~,,~,m, rotamer of amide —NH); 7.34(5Hj,s); 
9.60(lH/<,s)ppm. IR (CHC13) 3330, 1730, 1710, 1590, 
1540 cm~1. 
EX. 7 
Na-Methoxysuccinylalanyl-Ng-carbobenzoxyornithine 
phenacyl ester (8) 
H1, Hb 
Bk 0 O 
11‘ H, um, n .1 O 
N . 
II | HI II M 
H}, H}, o " CH3” H] O 
m 
The title compound was prepared from Na-carboben 
zoxy-L-ornithine phenacyl ester hydrochloride follow 
ing an analogous procedure to that described for 6. The 
product was crystallized from ethyl acetate/diethyl 
ether to give 0.46 g (0.8 mmole) (46% yield) of a crys 
talline powder mp l12°—113' C. lI-l-NMR (CDCl3) 8 
l.36(3Ha,d,J=8Hz); 1.40~2.20(4H1,,m); 2.44(2H¢,app. t, 
J =8Hz); 2.64(2Hc',app. t, J=8Hz); 3.18(2Hd,m); 
3.66(3l-l¢,s); 4.36-5.00(2Hf,m); 5.10(2H8,s); 5.46(2H;,,s); 
5.80(ll-l,-,m, rotamer of amide —NH); 6.56(ll-lj,m, 
rotamer of amide —NH); 7.10(1Hk,m, rotamer of amide 
—NH); 7.34(5H1,s); 7.63(3H,,,,,,,',,,,app. dd, Jm=8Hz, 
J,,,,,,',=2HZ); 8.06(2Ha,0',app. dd, Jam=8Hz), 
J.,,,=2Hz)ppm. IR (CHC13) 3330, 1755, 1730, 1645, 
1600, 1540 cm-1. 
EX. 8 
Na-Methoxysuccinylalanyl-N5-carbobenzoxyornithine 
(9) 
9 
H, j 
H, o 
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This compound was prepared from 8 according to an 
analogous procedure to that described for 7. Upon 
evaporation of the eluent solvent under reduced pres 
sure 0.3 g (0.75 mmole)(68% yield) of a transparent oil 
was obtained. lI-l-NMR (CDC13) 6 l.36(3H,,,d, 
J =8Hz); l.40-l.90(4Hb,m); 2.56(4Hc,¢',app. t, J =8Hz); 
3.23(2Hd,m); 3.66(3H,,s); 4.40-4.80(2Hf,m); 5.10(2Hg,s); 
6.80-7.l0(2H,-,m, rotamer of amide —NH); 7.34(5Hj,s); 
lO.lO(lHk,s)ppm. IR (CHCI3) 3330, 1730, 1710, 1590, 
1540 cm- 1. 
EX. 9 
Na-Methoxysuccinyl-Ng-Carbobenzoxyornithine (10) 
10 
Ho Hb 
CHBdO N 
II I 
0 HI)’ Hb' Hg 
OH] 
“3 II 
A suspension of 2(0.86 g,3.8 mmoles) and Ns-car 
bobenzoxy-L-ornithine (l g, 3.8 mmoles) in DMF were 
stirred during and after the addition of triethylamine 
(0.38 g, 3.8 mmoles) at room temperature. The progress 
of the reaction was monitored by TLC (10% acetic acid 
in ethyl acetate), upon completion of the reaction (24 h), 
the formed triethylamine salt was ?ltered and the ?l 
trate coevaporated with toluene under vacuum. The 
residue, containing the product, was dissolved in a 50:50 
mixture of ethyl acetate/0001M aqueous HCI (30 mL). 
The organic layer was washed with water (30 mL) and 
brine (30 mL); dried (5 g of MgSO4) and evaporated 
under reduced pressure. The residue was chromato 
graphed on 30 g of silica gel column (2X50 cm). The 
desired product was eluted with 4% methanol in chlo 
roform. Upon evaporation of the eluent solvent under 
reduced pressure, 1.4 g (3.6 mmoles) (96.7% yield) of an 
oil was obtained. The phenacyl ester derivative was 
' recrystallized from ethyl acetate/hexane to give a crys 
talline powder mp l12°—ll3° C. lH-NMR (CDCl3) 8 
l.50-2.00(4Ha,m); 2.44(2Hb,app. t, J = 8H2); 
2.64(2Hb-,appt. t, J=8Hz); 3.23(2Hc,m); 3.66(3Hd,s); 
4.30-4.80(1H,,m); 5.l0(2Hf,s); 7.20(lHg,m, rotamer of 
10 
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amide —NH); 7.40(5Hh,s); 8.l3(lH,-,m, rotamer of 
amide —NH); 9.46(lI-Ij,s)ppm. IR (CHC13) 3320, 1720, 
1700, 1660, 1540 crn-l. 
EX. l0 
Na-Methoxysuccinyl-N5-carbobenzoxyornithylalanine 
t-butyl ester (1 1) 
ll 
Hh 
HI: 
0 
>=0 
H,-—N He 
it, He 
H: 
He 
Hd Ed 0 Hf O 
“H 0M m1!‘ Hg " b 30) N OC(CH3)31, u | Hg n U 
0 Ha- Hd' Hi CHste) 
This compound was prepared from 10 according to 
an analogous procedure to that described for 14. The 
product (1 l) was crystallized from ethyl acetate/hexane 
to give 1.7 g (3.3 mmoles) (87% yield) of a white crys 
talline powder mp l33°—l35° C. 1I-I-NMR (CDC13) 8 
l.36(3Ha,dd, J=8Hz); l.46(9Hb,s); 1.50-2.20(4H¢,m); 
2.44(2Hd,app. t, J =8Hz); 2.64(2Hd',app. t, J=8Hz); 
3.2.3(2He,m); 3.66(3Hf,s); 4.00-4.52(2Hg,m); 5.l0(2H;,,s); 
6.80~7.20(3Hj,m, rotamer of amide —NH); 
7.40(5Hj,s)pprn. 1R (CHC13) 3330. 1735, 1725, 1590, 
1540 cm“ 1. 
EX. ll 
Na‘Methoxysuccinyl-N5-carbobenzoxyornithylalanine 
(12) 
CI-Ik-O 
u i‘ “I u 
This compound was prepared from 11 according to 
an analogous procedure to that described for 15. The 
product (12) was crystallized from ethyl acetate/hexane 
to give 0.2 g (0.5 mmole) (48% yield) of a crystalline 
powder, mp l47‘-148‘ C. lH-NMR (CDCl3)6 
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rotamer of amide —NH); 6.80-7.20(2H,-,m, rotamer of 
amide —NH); 7.34(5H_,-,s); 9.36(lHk,s)ppm. nucncb) 
3330, 1730, 1645, 1590, 1540¢m—. 
EX. l2 
Na-Methoxysuccinyl-N¢-carbobenzoxylysine ( l 3)_ 
"r 
H 
o f 
>=o 
Hr-N H: 
He 
He 
Ha Ht 
Ha 
Ha 
H5 Hg 0 
"He 
CHMO 0"; 
u | **= ll 
0 By By Hf O 
This compound was prepared from N.-carbobenzoxy~ 
, L-lysine according to an analogous procedure to that 
described for 10. The product was crystallized from 
chloroform/hexane to give 1.35 g (3.42 mmoles) (90% 
yield) of a crystalline powder, mp 85’—86' C. ‘H 
NMR(CDC1.1)8 1.50-2.00(6Ha,m); 2.44(2Hb,app. t, 
J=8Hz); 2.64(2Hb,app. t, J=8Hz); 3.23(2H¢,m); 
3.66(3Hd,s); 4.30—4.80(lH¢,m); 5.l0(2l-I/,s); 7.20(ll-l,,m, 
rotamer of amide -—NH); 7.40(5Hh,s); 8.l3(lHi,m, ro 
tamer of amide-NH); 9.46( l H,-,s)ppm. IR(CHCL1) 3320, 
177720, 1705, 1660, 1535 cm“ ‘. Elemental analysis cal’d for 
C19H2;N¢O1: C,57.87;H,6.64;N,7. 10. Found: 
C,57‘.87;H,6.67;N,7.09. 
EX. 13 
Na-MethoxysuccinyhNe-carbobenzoxylysylalanine 
t-butyl ester (14) 
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The carboxylic acid function of 13 (3.8 mmoles) was 
activated with N-hydroxysuccinimide (0.4 g, 3.8 
mmoles) using N,N’-dicyclohexylcarbodiimide (0,8 g, 
3.8 mmoles) in THF at 0° C. The cold reaction was 
stirred for one hour and stored in the refrigerator over 
night (14 h). The precipitated urea was ?ltered under 
vacuum and washed with a small amount of THF. 
L-Alanine t-butyl ester (0.7 g, 3.8 mmoles) was added 
as a solid to an ice-cooled THF (7 mL) solution of the 
activated ester (above). Triethylamine (0.38 g, 3.8 
mmoles) in THF (0.5 mL) was added dropwise (10 min) 
to the ?ne suspension. The formed precipitate was ?l 
te‘red after 1 h and the ?ltrate evaporated under reduced 
pressure. The residue, containing the product, was 
chromatographed on 20 g of silica gel column (1X50 
cm). Impurities were eliminated by ?rst passing 50 mL 
of methylene chloride and subsequently the compound 
was eluted with 3% methanol in methylene chloride. 
Upon evaporation of the eluent solvent under reduced 
pressure an oil was obtained. The latter was crystallized 
from ethyl acetate/hexane to give 1.67 g (3.1 mmoles) 
(82% yield from 11 of white crystalline powder, mp 
l55'—157' C. lI-I-NMR (CDCl3) 8 l.36(3Ha,dd, 
J =8Hz); 1.46(9H;,,s); l.50-2.20(6H¢,m); 2.44(2H4,app. t, 
J =8Hz); 2.64(2Hd',app. t, J =8Hz); 3.23(2H¢,m); 
3.66(3Hf,s); 4.00—4.52'(2Hg,m); 5.10(2H;,,s); 6.80—7.20( 
3H,-,m, rotamer of amide —NH); 7.40(5Hj,s)ppm. 
IR(CHC13) 3330, 1735, 1725, 1590, 1540 cm—1. Elemen 
tal analysis cal’d for Cz5H37N3091 
C,6l.08;l-I,7.59;N,8.55. Found: C,6l.08;H,7.60;N,8.53. 
EX. 14 
Na-Methoxysuccinyl-N¢-carbobenzoxylysylalanine 
(1 5) 
5,008,245 
EX. 18 
Preparation of an ether alcoholic solution of 
diazomethane, with a Diazald distillation kit ’ 
Ethanol, 95% (8 mL) was added to a solution of 
potassium hydroxide (1.79 g) in water (2.7 mL) in a 50 
mL distilling ?ask ?tted with a dropping funnel and an 
ef?cient condenser set downward for distillation. The 
condenser was connected to two receiving ?asks in 
series, the second containing 20 mL of diethyl ether. 
The inlet tube of the second receiver was dipped below 
the surface of the ether. Both receivers were cooled to 
0‘ C. The ?ask containing the alkali solution was heated 
in a water bath to 65' C., and a solution of Diazald 
(N-methyl-N-nitroso-p-toluenesulfonamide) (7.2 g, 33.0 
mmole) in ether (70 ml) was added through the drop 
ping funnel over about 30 min. The rate of distillation 
was approximately equal to the rate of addition. When 
the dropping funnel was empty, another 20 mL of ether 
was added slowly and the distillation was continued 
until the distilling ether was colorless. The combined 
ethereal distillate contained about 1 g (33.0 mmoles) of 
diazomethane based on the amount of Diazald used. 
Extreme care is warranted during and after the prepara 
tion of diazomethane. Care must be taken to avoid pos 
sible explosions by thoroughly checking the glassware 
for cracks and scratches, heating the alkali solution with 
a water bath (not to exceed 75‘ C.) and keeping the 
generated diazomethane solutions at or below 5' C. 
EX. 19 
N-t-Boc-L-prolyl chloromethyl ketone (19) 
O O 
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The procedure of Digenis et al.39 was followed for 
the preparation of compound 19. 
Isobutylchloroformate (2.1 g. 15.3 mmoles) was 
added to a solution of triethylamine (1.55 g, 15.3 
mmoles) and t-Boc-L-proline (3.3 gm, 15.3 mmoles) in 
diethyl ether (30 mL) was cooled to -15‘ C. The reac 
tion mixture was stirred at this temperature for 10 min, 
at which time a cooled solution (0° C.) of diazomethane 
(l g, 32.4 mmoles) in diethyl ether (200 mL) was added. 
The vessel, equipped with a calcium sulfate drying tube, 
was stirred at 0' C. in the hood overnight (14 h). The 
organic layer was washed subsequently with saturated 
bicarbonate solution (30 mL), water (30 mL) and brine 
(30 mL). After drying with 15 g of MgSO4, the solvent 
was evaporated under reduced pressure to yield of yel~ 
low oil. 
Hydrogen chloride gas was bubbled through an ice 
cooled solution of the yellow oil (N-t-Boc-L-proyl azo 
methyl ketone) in diethyl ether (50 mL) for 60s. The 
reaction was stopped after 10 min by diluting with 
cooled diethyl ether (50 mL) and evaporated under 
34 
vacuum. The residue, containing the product, was chro 
matographed on 50 g of silica gel column (3X75 cm) 
Impurities were eliminated by ?rst passing 100 mL of 
10% hexane in chloroform and subsequently the com 
pound was eluted with chloroform. Upon evaporation 
, of the eluent solvent under reduced pressure a transpar 
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cut oil was obtained. The latter (19) was then crystal 
lized from chloroform/hexane to give 3.1 g (12.5 
mmoles) (82% yield) of colorless crystals m.p. 47°—49° 
C. 1I-I-NMR (CDC13) 8 1.46(9Ha,s); l.86—2.l6(4Hb,m); 
3.33-3.76(2Hc,m); 4.36(2Hd,s); 4.40—4.80(lHc,m)ppm. 
IR (Nujol) 1740, 1690 cm- 1. Elemental Analysis Cal’d. 
for C11H1gCINO3: C,53.33;H,7.32;N,5.65. 
Found,C,53.46;H,7.35;N,5.56. 
The NMR, IR and Elemental analysis were found to 
be identical to those reported by Digenis et al.39. 
EX. 20 
N-[(N-t-Boc-L-propyDmethyl]isopropylamine (20) 
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This compound was synthesized by a modi?ed proce 
dure of Digenis et al39. 
Isopropylamine (7.4 g, 125.0 mmoles) was slowly 
added to a cooled solution (0° C.) of 19 (3.1 g, 12.5 
mmoles) in diethyl ether and stirred overnight at room 
temperature (14h). The salt formed was ?ltered and the 
?ltrate evaporated under vacuum. The oil was chro 
matographed on 30 g of silica gel column (2X25 cm). 
Impurities were eliminated by ?rst passing 50 mL of 1% 
methanol in chloroform and subsequently the com 
pound was eluted with 5% methanol in chloroform. 
Upon evaporation of the eluent solvent under reduced 
pressure 3.1 gm (11.4 mmoles) (90.8% yield) of an oil 
was obtained. lI~I-NMR(CDC13) 8 0.93-l.31(6Ha,app. 
d, J=7Hz); l.46(9Hb,s); 1.86-2.16(4Hc,m); 2.83(lH,1,m); 
3.30—3.73(5He‘/,8,m); 4.30(1H/,,app.t,J =8Hz)ppm. I 
(CHCI3)3330, 1695 cm-l. 
The NMR and IR of this compound were found to be 
identical to those reported by Digenis et al.39. 
EX. 21 
p-Nitrophenyl-N-[(N-Boc-L-prolyDmethyl]-N-isopro 
pyl-carbamate (21) 
CH3“) h, f 21 
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the procedure of Digenis et al.39 was followed for the 
preparation of compound 21. 
p-Nitrophenylchloroformate (2.75 g, 13.6 mmoles) 
was added as powder to an ice-cooled solution of 20 (3.1 
g, 11.4 mmoles) in THF (10 mL) and triethylamine (1.15 
g, 11.4 mmoles) at 5' C. The mixture was stirred at 5' C. 
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for 2 h, the formed triethylamine salt ?ltered and the 
?ltrate evaporated under vacuum. The crude oil was 
dissolved in ethyl acetate and washed with water, 10% 
aqueous citric acid (30 mL), water (30 mL) and brine 
(30 mL); dried (10 g of MgSO4) and evaporated under 
reduced pressure. The residue, containing the product, 
was dissolved in a small amount of chloroform and 
chromatographed on 40 g of silica 'gel column (2X50 
cm). The impurities were eliminated by ?rst passing 
chloroform and subsequently the compound was eluted 
with 50:1 chloroform in ethyl acetate. Upon evapora 
tion of the eluent solvent under reduced pressure 4.6 g 
(10.7 mmoles) (94% yield) of a transparent oil was ob 
tained. lH-NMR (CDC13) 5 1.l3(3Ha,app. d, J =8Hz); 
1.20(3Ha',add. d, J = 8H1); l.46(9Hb,s); 
l.86—2.l6(4Hc,m); 3.56-3.84(2Hd,m); 4.20,4.32(2H,, cen 
ter of a set of dd, overlapping with another set, 
J=20Hz, rotamers of the CH2“) geminal system); 
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room temperature (1 h). The product was collected by 
vacuum ?ltration and washed with ethyl acetate. A 
second crop was collected after concentrating the solu 
tion. The latter was crystallized from ethanol/diethyl 
ether to give 1.46 g (3.8 mmoles) (68% yield) of a tan 
powder, mp 179'-182° C. (lit.39 mp l90°-l93° C.). 1H 
NMR (DMSO-dg) 8 l.l3(3Ha,app. d, J =8l-lz); 
J=l0Hz)ppm. IR (Nujol) 1740, 1720, 1610, 1595, 1520 
cm-1. 
EX. 23 
p-Nitrophenyl 
N-[Methoxysuccinyl-(Ne-carbobenzoxy?ysylalanyl 
prolylrnethyl]-N-isopropylcarbamate (44b, the LLD 
4.50(2Hf, app. t, J =8Hz); 4.53-4.80(4H;,m); diastereomer) 
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IR (CHCl3) 1740, 1710, 1690, 1595, 1520 cm-1. 
The NMR and IR for this compound were found to 
be identical to those reported by Digenis et al.39 
EX. 22 
p-Nitrophenyl-N-(L-Prolylmethyl)-N-isopropylcarba 
' mate Hydrochloride (22) 
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The procedure of Digenis et al.‘ was followed for the 
preparation of compound 22. . 
Three additions of hydrogen chloride gas (30s each) 
were introduced at 10 min intervals to an ice-cooled 
ethyl acetate (20 mL) solution of 21 (1.6 g, 5.6 mmoles) 
and formic acid (98%) (2.4 mL). The solution was 
stirred at 5' C. for 1 h, then allowed to equilibrate to 
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To a cooled solution (—l5' C.) of 15 (0.85 mmoles) 
and N-methylmorpholine (0.85 mmoles) in THF (5 mL) 
isobutylchlorofonnate (0.13 g, 0.94 mmoles) in acetoni 
trile (3 mL) was added. After 10 min, 22 (0.4 g, 1 
mmole) was added as a solid and N-methylmorpholine 
(0.1 g, 1 mmole) as an acetonitrile solution (2 mL). The 
reaction mixture was allowed to warm to 5' C. in 30 min 
and stirred (3 h). The reaction mixture was ?ltered, the 
filtrate was evaporated under vacuum and the residue 
was redissolved in methylene chloride (25 mL). The 
organic solvent was subsequently washed with water 
(25 mL), 10% aqueous citric acid (25 mL), water (25 
mL) and brine (25 mL); dried (5 g of M3504) and evap 
orated under reduced pressure. The residue, containing 
the product, was chromatographed on 10 g silica gel 
column (1 X25 cm). The impurities were eliminated by 
?rst passing 25 mL of methylene chloride and 25 mL 
2% methanol in methylene chloride. Upon evaporation 
of the eluent solvent under reduced pressure an amor 
phous powder was obtained. The amorphous powder 
containing 44a and 44b was dissolved in chloroform and 
applied to a preparaative TLC plate (100 mg/plate) and 
developed two to three times with 4% methanol in 
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ethyl acetate. The two bands were separately scraped 44b. Tha amorphous powder containing 44a and 44b 
from the plate and extracted with 20% methanol in was dissolved in chloroform and applied to a prepara 
chloroform (3X25'mL). The eluent solvent was evapo- tive TLC plate (100 mg/plate) and developed two or 
rated under reduced pressure to give an amorphous three times with 4% methanol in ethyl acetate. The 
powder. The lower band was pure 44a. The desired 5 lower band contained 44a while the upper band con 
product (44b)isolatedas0.23 g(0.3 mmoles)(35% yield) tained 44b. The two bands were separately scraped 
of a white amorphous powder, mp 46°-47° C., was from the plate, extracted with 20% methanol in chloro 
obtained from the upper TLC band. lI-l-NMR (CDC13) form (3X25 rnL) and eluent solvent evaporated under 
8 1.13(3H,,,app.d, J=7Hz, rotamer of l); l.20(3Ha'. reduced pressure. The desired product (44a) isolated as 
,app.d, J=7Hz, rotamer of l); 1.36(3Hb,d, J =8Hz); 10 0.33 g (0.43 mmoles) (50% yield) of a white amorphous 
l.40—-2.22(l0I--l¢,m);v 2.44(2I-Id,app.t, J =8Hz); powder, mp 50_‘—51° C., was obtained from the lower 
2.64-(2Hd',app.t, J=8Hz); 3.l8(2He,m); 3.33(2Hf,app.t, TLC band. 1H-NMR (CDCl3) 6 1.06—l.28(6H,,,a',m, 
J=8Hz); 3.66(2Hg,s); 4.30(2H;,, center of 2 sets of dd, rotamer of l); 1.32(3Hb,d, J =8Hz); l.38-2.32(10Hc,rn); 
J =20Hz, rotamer of the CH2“) geminal system); 2.46(2Hd,app.t, J =8Hz); 2.64(2Hd',app.t, J=8Hz); 
4.53(1Hi,app.t, J =8Hz); 4.63(lHj,app.t, J=8Hz); 15 3.20(2H¢,m); 3.36(2Hf,m); 3.66(3Hg,s); 4.20,432(2H;,, 
4.80(2Hk,1,m); 5.lO(2H,,,,s); 5.42(1H,,,m); 6.70-7.l0(- center of a set of dd, overlapping with another set, 
211mm, rotamer of amide —NH); 7.24(1H,,,app.d, J=20Hz, rotamers of the CH2“) geminal system); 
J=10Hz, rotamer of l); 7.28(lHp',app.d, J =10Hz, 4.53(lH,-,app.t, J=8Hz);- 4.63(1Hj,app. t, J=8Hz); 
rotamers of l); 7.34-(5Hq,app.s); 8.20(1H,,app.d, 4.80(2Hk,1,m); 5.10(2H1,s); 5.42(1H,,,,m); 
J =10Hz, rotamer of l); 8.25(lH,/,app.d, J=l0I-lz, 20 6.36-7.08(2H,,,m, rotamers of amide —NH); 
rotamer of l)ppm. IR (CHCl3) 3310, 1730, 1650, 1520, 7.35(5Hp,app.s); 8.20(1Hq,app.d, J=10Hz, rotamers of 
735, 700 cm-1. Elemental analysis cal’d for l); 8.25(lHq',app.d,J=lOHz, rotamers of l)ppm. IR 
C3gH50N6O12: C,58.30;H,6.44;N,10.74. Found: (CHCl3) 3310, 1730, 1650, 1520, 735, 700 cm-1. Ele 
C,58.19;H,6.50;N,10.64. mental Analysis cal’d for C33H50N6O12: C,58.30; 
25 H,6.44; N,l0.74. Found: C,58.47; H,6.48; N,l0.67. EX. 24 
p-Nitrophenyl EX‘ 25 
N-[Methoxysuccinyl-(Nsg-carbobenzoxy)lysylalanyl- p-Nitrophenyl 
'prolylmethyl]-N-isopropylcarbamate (44a, the LLL N-[Methoxysuccinyl-(Ne-benzoyl)lysylalanylprolylme 
diastereomer) 30 thyl]-N-isopropylcarbamate (45b, the LLD 
44a 
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The title compound was prepared from 15 and 22 diastereomer) 
following a procedure analogous to that described for 























